Value investors need patience when waiting for the story unfolding for new stage biotech companies. For Kerx (KERX), sales execution, if successful, will support a higher share price for the stock. Kerx is building its sales force in an effort to build physician awareness for the company’s product reimbursement. The renal sales force is improving its performance steadily. In its first quarter, Kerx’s new scripts came from 70% switch patients and 30 percent from new patients. Kerx increased its sales force from 60 to 95. This will raise the number of reps and hence the reps to nephrologist ratio. Increasing the frequency reps connect with doctors will improve prescription growth. Kerx has plenty of work ahead for Auryxia. The TAM for the CKD market is big, but Kerx is falling short on delivering higher sales. Sales for Renvela in Europe is secondary in importance, but efforts will pick up in the quarter ahead. Read more free articles on biotech stocks.Syergy Bottomed at $3Intrexon (XON) Could Trade to $30Why Bankruptcy is Not Happening for ValeantRelypsa will Survive